News

InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users

LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction. The therapies are designed to reduce or prevent […]

Read more

Holtz steps down as CEO

After 10 years, Dr. Holtz has stepped away from CEO and managerial duties at InterveXion to focus on ventures and technologies in pharmaceutical production.

Read more

InterveXion publishes results of Phase 1a study of ch-mAb7F9

The company is pleased to report publication of the results of the first human study of ch-mAb7F9.  The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an anti-methamphetamine monoclonal antibody, in healthy volunteers. […]

Read more

Two Anti-METH Antibodies Reduce METH-Induced Locomotor Effects and Favorably Alter METH Kinetics in Rats

InterveXion and UAMS have published a new manuscript describing the effects of two monoclonal antibodies designed to treat METH abuse. The studies compare the two antibodies and describe the factors that resulted in the choice of mAb7F9 for clinical development. Abstract – This lead candidate selection study […]

Read more

Anti-METH Antibody Shortens the Time Rats are Affected by Repeated Doses of METH

A new manuscript published by UAMS describes the shortened duration of repeated METH dose effects in rats over a month following administration of mAb7F9. Abstract – This study assessed clinical scenarios of continuing monoclonal antibody (mAb) treatment for (+)- methamphetamine (METH) addiction, and the implications of missing […]

Read more

New Publication Describes ch-mAb7F9 Bioequivalence Studies

InterveXion and UAMS have published a new manuscript describing the development of the ch-mAb7F9 antibody and early studies demonstrating it’s bioequivalence to the murine mAb7F9. Abstract - Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a […]

Read more

FDA grants meeting to discuss Phase 1a results and plans for Phase 1b

InterveXion has been granted a meeting with FDA in January 2014 to discuss the development program for ch-mAb7F9. The purpose of the meeting is three-fold: 1) to discuss the results of the Phase 1a study, 2) to confirm that the proposed nonclinical studies will support a Phase […]

Read more

All Planned Follow-Ups Completed in First Human Study of ch-mAb7F9

InterveXion Therapeutics reports that all subjects have completed all planned follow-up appointments in the first clinical study of ch-mAb7F9, the company’s first investigational anti-methamphetamine antibody product. Forty-two (42) non-METH using volunteer subjects were dosed with antibody or placebo in the study starting in May 2012. Because of […]

Read more

InterveXion Completes Planned Dosing in Phase 1a Study of ch-mAb7F9

LITTLE ROCK – InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions. The medication is expected to significantly reduce or prevent the euphoric rush […]

Read more

A Vaccine to Curb Addicts’ Highs

Chief Scientific Officer, Mike Owens, Ph.D., was quoted in the Wall Street Journal discussing the potential of anti-methamphetamine antibodies to be available in the right amount at the right time. Read the essay…

Read more